How to boost clinical trial access and make patients health-empowered
September 17, 2024 | Activated Patient, Inclusion, Patient Participation, Patient-centricity, Pharma, clinical trials
Clinical research is becoming more patient-centric, but there’s still more that needs to be done to make clinical trials available to everyone. This could include wider participation.
How to increase patient participation
Pharmaceutical companies are working on overturning this statistic by designing and building trials that centre around participant needs. This includes greater patient involvement in trial design; more opportunities for treatment at home; fewer tests and assessments; and new technologies for support and monitoring.
However, it seems clinical trial participation is not for everyone. Could it be because a huge amount of trust, awareness and understanding is needed to become a clinical trial participant?
Where the ‘activated’ patient comes in
According to health researcher Judith Hibbard, activated patients, who are actively engaged in managing their health and advocating for themselves, are better equipped to handle health conditions and contribute to treatment decisions.
Although, it’s not always an equal starting point because not everyone will be at activated status. Because initiatives often engage with those who are already activated and have high levels of health literacy, The complexity of clinical trial information means that some patients defer decision-making to their doctors. It may not be on purpose, but this excludes many from potentially life-changing medicines.
Empower patients through clinical trials
This may be an opportunity for those in charge of clinical trials to take a leading role in helping patients to become activated, creating a push-pull that works in all directions. Consider clinical trial education and awareness resources developed with everyone in mind, helping to bridge the knowledge gap and supporting people to make informed decisions for their own health.
Shift towards community-inclusive trials
The industry is already beginning to shift towards more patient-centred clinical trial recruitment and providing trial information that speaks to all. But that’s just the start. Perhaps it’s time to bring whole communities into contact with the clinical research world instead, giving everyone an opportunity to share their opinions and ideas —, a chance to feel part of something bigger.
It might not be easy, but it will be worth it.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
A seat at the table: what the EU HTA reforms really ask of patient involvement
The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.
Why faster trials make participant understanding more important than ever
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.
Older trial participants reject bad design, not technology
Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.
5 key takeaways from the Patient Centricity and Engagement Conference
Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.
It’s time to stop calling adverse events ‘manageable’
A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.
The value: why localisation pays off across global trials
Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.
The solution: Good localisation doesn’t feel translated
Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.
Healthcare information is becoming easier to access. Trust isn’t.
Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.
It was never reluctance: What ASCO 2026 revealed about clinical trial recruitment
ASCO 2026 highlighted that low clinical trial recruitment is driven less by patient reluctance and more by gaps in awareness, communication, accessibility and patient education.